Background and aim
The aim of this work was to compared the effect of lipid lowering drugs among FH subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE.
Methods 
We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n=22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n=44).
Results 
The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4 % and -36.4%, respectively (p = 0.030).
Conclusions
Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for more efficient management of FH.

05 - LIPID-LOWERING RESPONSE IN SUBJECTS WITH THE P.(LEU167DEL) MUTATION IN APOE GENE